下肢動脈硬化閉塞癥的藥物治療_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 時德

重慶醫科大學附屬第一醫院血管外科重慶市血管外科中心（重慶 400016）;

Corresponding?author：

時德, Email: sdpwqlsl@126.com

Keywords：

DOI：

10.7507/1007-9424.20150236

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 時德. 下肢動脈硬化閉塞癥的藥物治療. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(8): 904-909. doi: 10.7507/1007-9424.20150236 Copy

1.	Liuzzo G. Atherosclerosis:an inflammatory disease. Rays, 2001, 26(4):221-230.
2.	Pappalardo F, Scandroglio AM, Potapov E, et al. Argatroban anticoa-gulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol, 2012, 78(3):330-335.
3.	Agarwal S, Ullom B, Al-Baghdadi Y, et al. Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol, 2012, 28(1):106-110.
4.	陳怡琳, 施仲偉.抗凝新藥利伐沙班臨床研究進展.心血管病學進展, 2009, 30(5):810-813.
5.	Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban-an oral, direct factor Xa inhibitor-has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol, 2008, 143(1):92-99.
6.	Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factorⅩa inhibitor. J Thromb Haemost, 2005, 3(3):514-521.
7.	Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol, 2006, 13(5):357-361.
8.	喬文豪, 王秀, 王佳麗, 等.抗血小板藥物藥理作用和臨床應用的研究進展.安徽醫藥, 2014, 18(9):1621-1625.
9.	Divani AA, Zantek ND, Borhani-Haghighi A, et al. Antiplatelet therapy:aspirin resistance and all that jazz! Clin Appl Thromb Hemost, 2012, 19(1):5-18.
10.	劉宇, 曹清心, 趙仙先.阿司匹林抵抗的研究進展.國際心血管病雜志, 2014, 41(4):249-251.
11.	Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther, 2014, 141(1):69-78.
12.	張捷青, 呂遷洲.抗血小板藥物——西洛他唑的臨床應用進展.中國新藥與臨床雜志, 2013, 32(2):101-104.
13.	Squires H, Simpson E, Meng Y, et al. A systematic review and eco-nomic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in People with peripheral arterial disease. Health Technol Assess, 2011, 15(40):1-210.
14.	Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication:results of a randomized, multicenter trial. Arch Intern Med, 1999, 159(17):2041-2050.
15.	Geng DF, Liu M, Jin DM, et al. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation:a meta-analysis of 5 821 patients. Cardiology, 2012, 122(3):148-157.
16.	Heo SH, Lee JS, Kim BJ, et al. Effects of cilostazol against the prog-ression of carotid IMT in symptomatic ischemic stroke patients. J Neurol, 2013, 260(1):122-130.
17.	Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance. J Am Coll Cardiol, 2006, 47(1):27-33.
18.	Kajiwara I, Soejima H, Miyamoto S, et al. Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina. Thromb Res, 2011, 128(6):547-551.
19.	Cohen RA, Zitnay KM, Weisbrod RM. Accumulation of 5-hydroxy-tryptamine leads to dysfunction of adrenergic nerves in canine coronary artery following intimal damage in vivo. Circ Res, 1987, 61(6):829-833.
20.	任師顏, 王非, 錢松屹, 等.鹽酸沙格雷酯治療下肢動脈硬化閉塞癥的療效觀察.中日友好醫院學報, 2012, 26(3):142-144.
21.	Kumakura H, Kanai H, Araki Y, et al. Effects of antiplatelet agents and other factors on neointimal proliferation in iliac artery stenting:intravascular ultrasound analysis. Ann Vasc Dis, 2009, 2(2):100-108.
22.	Chalouhi N, Jabbour P, Kung D, et al. Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms. Neuro-surgery, 2012, 71(3):710-714.
23.	汪忠鎬, 章海.內皮細胞襯里人工血管的實驗研究.心肺血管雜志, 1986, 5(4):52-57.
24.	[No authors listed]. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease:the Scandinavian Simva-statin Survival Study (4S). Lancet, 1994, 344(8934):1383-9138.
25.	中國成人血脂異常防治指南制訂聯合委員會.中國成人血脂異常防治指南.中華心血管病雜志, 2007, 35(5):390-419.
26.	趙心彬, 倪敏, 陶霞.他汀類藥物多效藥理作用及其機制研究進展.藥學實踐雜志, 2013, 31(1):19-21.
27.	Davis HR, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis, 2011, 215(2):266-278.

1. Liuzzo G. Atherosclerosis:an inflammatory disease. Rays, 2001, 26(4):221-230.
2. Pappalardo F, Scandroglio AM, Potapov E, et al. Argatroban anticoa-gulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol, 2012, 78(3):330-335.
3. Agarwal S, Ullom B, Al-Baghdadi Y, et al. Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol, 2012, 28(1):106-110.
4. 陳怡琳, 施仲偉.抗凝新藥利伐沙班臨床研究進展.心血管病學進展, 2009, 30(5):810-813.
5. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban-an oral, direct factor Xa inhibitor-has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol, 2008, 143(1):92-99.
6. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factorⅩa inhibitor. J Thromb Haemost, 2005, 3(3):514-521.
7. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol, 2006, 13(5):357-361.
8. 喬文豪, 王秀, 王佳麗, 等.抗血小板藥物藥理作用和臨床應用的研究進展.安徽醫藥, 2014, 18(9):1621-1625.
9. Divani AA, Zantek ND, Borhani-Haghighi A, et al. Antiplatelet therapy:aspirin resistance and all that jazz! Clin Appl Thromb Hemost, 2012, 19(1):5-18.
10. 劉宇, 曹清心, 趙仙先.阿司匹林抵抗的研究進展.國際心血管病雜志, 2014, 41(4):249-251.
11. Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther, 2014, 141(1):69-78.
12. 張捷青, 呂遷洲.抗血小板藥物——西洛他唑的臨床應用進展.中國新藥與臨床雜志, 2013, 32(2):101-104.
13. Squires H, Simpson E, Meng Y, et al. A systematic review and eco-nomic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in People with peripheral arterial disease. Health Technol Assess, 2011, 15(40):1-210.
14. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication:results of a randomized, multicenter trial. Arch Intern Med, 1999, 159(17):2041-2050.
15. Geng DF, Liu M, Jin DM, et al. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation:a meta-analysis of 5 821 patients. Cardiology, 2012, 122(3):148-157.
16. Heo SH, Lee JS, Kim BJ, et al. Effects of cilostazol against the prog-ression of carotid IMT in symptomatic ischemic stroke patients. J Neurol, 2013, 260(1):122-130.
17. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance. J Am Coll Cardiol, 2006, 47(1):27-33.
18. Kajiwara I, Soejima H, Miyamoto S, et al. Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina. Thromb Res, 2011, 128(6):547-551.
19. Cohen RA, Zitnay KM, Weisbrod RM. Accumulation of 5-hydroxy-tryptamine leads to dysfunction of adrenergic nerves in canine coronary artery following intimal damage in vivo. Circ Res, 1987, 61(6):829-833.
20. 任師顏, 王非, 錢松屹, 等.鹽酸沙格雷酯治療下肢動脈硬化閉塞癥的療效觀察.中日友好醫院學報, 2012, 26(3):142-144.
21. Kumakura H, Kanai H, Araki Y, et al. Effects of antiplatelet agents and other factors on neointimal proliferation in iliac artery stenting:intravascular ultrasound analysis. Ann Vasc Dis, 2009, 2(2):100-108.
22. Chalouhi N, Jabbour P, Kung D, et al. Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms. Neuro-surgery, 2012, 71(3):710-714.
23. 汪忠鎬, 章海.內皮細胞襯里人工血管的實驗研究.心肺血管雜志, 1986, 5(4):52-57.
24. [No authors listed]. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease:the Scandinavian Simva-statin Survival Study (4S). Lancet, 1994, 344(8934):1383-9138.
25. 中國成人血脂異常防治指南制訂聯合委員會.中國成人血脂異常防治指南.中華心血管病雜志, 2007, 35(5):390-419.
26. 趙心彬, 倪敏, 陶霞.他汀類藥物多效藥理作用及其機制研究進展.藥學實踐雜志, 2013, 31(1):19-21.
27. Davis HR, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis, 2011, 215(2):266-278.

Previous Article
下肢動脈硬化閉塞癥的血管腔內治療
Next Article
主髂動脈閉塞癥外科和腔內治療選擇

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

下肢動脈硬化閉塞癥的藥物治療

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content